The genomic profiling did not indicate a clear tumor-intrinsic genetic mechanism of resistance in either the metastatic or recurrent lesion, and the conclusions in the bulk transcriptome profiling were limited, since we could not directly associate the downregulation of AP-1 targets to T-cell exhaustion. The gene discussed is FOS; the disease is neoplasm.